IFM Investors Pty Ltd Has $28.46 Million Stake in Gilead Sciences, Inc. $GILD

Key Points

• IFM Investors Pty Ltd has increased its stake in Gilead Sciences, Inc. by 1.0%, now holding 256,664 shares valued at approximately $28.46 million.
• Insider Johanna Mercier recently sold 3,000 shares of Gilead stock for approximately $340,710, while CEO Daniel O'Day sold 10,000 shares valued at around $1.14 million.
• The company announced a quarterly dividend of $0.79 per share, representing a 2.8% dividend yield based on its current stock price.

IFM Investors Pty Ltd grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 256,664 shares of the biopharmaceutical company's stock after acquiring an additional 2,635 shares during the period. IFM Investors Pty Ltd's holdings in Gilead Sciences were worth $28,456,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in GILD. Ariel Investments LLC increased its position in shares of Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after purchasing an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC increased its position in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 109 shares during the last quarter. Swedbank AB increased its position in shares of Gilead Sciences by 0.8% in the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock worth $237,393,000 after purchasing an additional 16,663 shares during the last quarter. Focus Partners Wealth increased its position in shares of Gilead Sciences by 21.2% in the 1st quarter. Focus Partners Wealth now owns 142,666 shares of the biopharmaceutical company's stock worth $15,986,000 after purchasing an additional 24,930 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. acquired a new position in shares of Gilead Sciences in the 1st quarter valued at about $11,688,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

GILD has been the subject of several research reports. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a report on Friday, July 25th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a report on Friday, September 12th. UBS Group lifted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $117.17.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the transaction, the chief financial officer owned 160,110 shares in the company, valued at approximately $18,977,838.30. The trade was a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 82,000 shares of company stock valued at $9,390,030. Insiders own 0.27% of the company's stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded down $1.60 during trading on Monday, hitting $112.49. 7,257,534 shares of the company's stock traded hands, compared to its average volume of 8,080,683. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm's fifty day moving average price is $114.10 and its 200 day moving average price is $109.98. Gilead Sciences, Inc. has a twelve month low of $81.83 and a twelve month high of $121.83. The company has a market cap of $139.58 billion, a PE ratio of 22.41, a PEG ratio of 0.77 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the firm posted $2.01 EPS. The firm's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.